Vimarsana
Biggest News Aggregation in the World

Page 3 - Acticor Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acticor Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acticor Biotech Today - Breaking & Trending Today

ACTICOR Adapts Its ACTISAVE Clinical Study to Prepare the Registration of Glenzocimab for the Treatm - Vimarsana News

ACTICOR Adapts Its ACTISAVE Clinical Study to Prepare the Registration of Glenzocimab for the Treatm

- Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024- Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028PARIS--(BUSINESS WIRE)--Regulatory News:Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical s...

University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study - Vimarsana News

University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study

September 7th, 2023, the University of Birmingham and Acticor Biotech announce the full regulatory approval of LIBERATE clinical study.

Acticor Biotech Announces Results of Its Collaboration with Brainomix Limited - Vimarsana News

Acticor Biotech Announces Results of Its Collaboration with Brainomix Limited

Acticor Biotech announced the results of its collaboration with Brainomix Limited, to further explore the imaging datausing Artificial Intelligence from its phase 1b/2a ACTIMIS study. The ACTIMIS...

Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 - Vimarsana News

Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028

/PRNewswire/ -- DelveInsight's Medical Second Opinion Market Insights report provides the current and forecast market analysis, individual leading medical...

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research - Vimarsana News

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

26.05.2023 - Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces today that it will ...